Endocrine tumors of the pancreas.
The identification and description of a widely dispersed group of cells of common origin and biochemical characteristics, APUD cells, has allowed a better understanding and classification of endocrine tumors of the pancreas. Similarly, it has enabled the relationships between the endocrine tumors of the multiple endocrine neoplasia type I syndrome and the endocrine tumors of the pancreas to be better appreciated. This has facilitated both diagnosis and management of these conditions. The pluripotentiality of the cells of the APUD system combined with the certain existence of many unidentified peptides suggests the likelihood of other undescribed pancreatic endocrine tumors. Many of these are probably part of the heterogenous group of neoplasms currently designated as carcinoids, since their secretory products and exact cell types are not known. The recognition of the physiologic characteristics and cells of origin of these peptides, amines or other bioactive agents will allow delineation of the symptom complex and the identification of further functional tumors of the pancreas. The development of plasma radioimmunoassays for the various hormones and the appreciation of the specific clinical syndromes related to each tumor have enabled earlier diagnosis. The understanding of the hormonal physiopathologic functions has led to the evolution of specific therapeutic maneuvers. Provocative tests have allowed increased precision of the differential diagnosis, while selective arteriography and pancreatic venous sampling have greatly enhanced the accuracy of topical localization. The role of operation in tumor removal is still prominent, but malignant and recurrent tumors may now also be controlled with specific pharmacotherapy or appropriate endocrine cytotoxic agents. The use of peptides with antagonistic actions or the administration of specific antibodies to the active tumor products are areas of therapy that require further exploration.
D000328:Adult; D001079:Apudoma / Q000032:analysis / Q000175:diagnosis; D002276:Carcinoid Tumor / Q000175:diagnosis; D002648:Child; D003937:Diagnosis, Differential; D005755:Gastrins / Q000378:metabolism; D005934:Glucagon / Q000378:metabolism; D006801:Humans; D007223:Infant; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans; D009378:Neoplasms, Multiple Primary / Q000175:diagnosis; D010190:Pancreatic Neoplasms / Q000032:analysis / Q000175:diagnosis / Q000473:pathology / Q000503:physiopathology / Q000601:surgery; D010191:Pancreatic Polypeptide / Q000032:analysis; D013004:Somatostatin / Q000097:blood; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism; D015043:Zollinger-Ellison Syndrome / Q000175:diagnosis
D005755:Gastrins; D007328:Insulin; D014660:Vasoactive Intestinal Peptide; D013004:Somatostatin; D010191:Pancreatic Polypeptide; D005934:Glucagon